Vnitr Lek 2018, 64(9):867-873 | DOI: 10.36290/vnl.2018.119

Comorbidities in heart failure

Jiří Vítovec1,*, Lenka ©pinarová1, Jindřich ©pinar2
1 I. interní kardio-angiologická klinika LF MU a FN u sv. Anny v Brně
2 Interní kardiologická klinika LF MU a FN Brno, pracoviątě Bohunice

Comorbidities are important parts of care in patients with heart failure. Comorbidities, as well as their treatments, directly influence the course of heart failure. We present the most comorbidities a their therapy with regard to left ventricular dysfunction.

Keywords: comorbidities; heart failure

Received: July 18, 2018; Accepted: August 13, 2018; Published: September 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vítovec J, ©pinarová L, ©pinar J. Comorbidities in heart failure. Vnitr Lek. 2018;64(9):867-873. doi: 10.36290/vnl.2018.119.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37(27): 2129-2200. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehw128>. Go to original source... Go to PubMed...
    2. ©pinar J, Hradec J, ©pinarová L et al. Summary of the 2016 ESC Guidelines on the diagnosis and treatment of acute and chronic heart failure. Cor Vasa 2016; 58(5): 455-494. Go to original source...
    3. Windecker S, Kolh P, Alfonso F et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014; 35(37): 2541-2619. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehu278>. Go to original source... Go to PubMed...
    4. von Haehling S, Anker SD. Treatment of cachexia: an overview of recent developments. J Am Med Dir Assoc 2014; 15(12): 866-872. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jamda.2014.09.007>. Go to original source... Go to PubMed...
    5. Suter TM, Ewer MS. Cancer drugs and the heart: Importance and management. Eur Heart J 2013; 34(15): 1102-1111. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehs181>. Go to original source... Go to PubMed...
    6. Newhouse A, Jiang W. Heart failure and depression. Heart Fail Clin 2014; 10(2): 295-304. Dostupné z DOI: <http://dx.doi.org/10.1016/j.hfc.2013.10.004>. Go to original source... Go to PubMed...
    7. Niessner A, Tamargo J., Koller L et al. Non-insulin antidabetic pharmacotherapy in patients with established cardiovascular disease: a position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. Eur Heart J 2018; 39(24): 2274-2281. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehx625>. Go to original source... Go to PubMed...
    8. Seferovic PE, Petrie MC, Filippatos GS et al. Type 2 diabetes mellitus and Heart failure: a position paper of the European Society of Cardiology. Eur J Heart Fail 2018; 20(5): 853-872. Dostupné z DOI: <http://dx.doi.org/10.1002/ejhf.1170>. Go to original source... Go to PubMed...
    9. Kubíčková M, ©mahelová A. Diabetes mellitus a srdeční selhání. Kardiol Rev Int Med 2014; 16(5): 352-354.
    10. Vítovec J, ©pinar J, ©pinarová L. Empagliflozin a srdeční selhání. Hypertenze a KV prevence 2016; 5(2): 19-23.
    11. Giagulli VA, Moghetti P, Kaufman JM et al. Managing erectile dysfunction in heart failure. Endocr Metab Immune Disord Drug Targets 2013; 13(1): 125-134. Go to original source... Go to PubMed...
    12. Anker SD. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 2003; 107(15): 1991-1997. Dostupné z DOI: <http://dx.doi.org/10.1161/01.CIR.0000065637.10517.A0>. Go to original source... Go to PubMed...
    13. Desai AS. Hyperkalemia in patients with heart failure: incidence, prevalence, and management. Curr Heart Fail Rep 2009; 6(4): 272-280. Go to original source... Go to PubMed...
    14. Tavazzi L, Maggioni AP, Marchioli R et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372(9645): 1231-1239. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140-6736(08)61240-4>. Go to original source... Go to PubMed...
    15. Widimský J Jr, Filipovský J, Ceral J et al. Doporučení pro diagnostiku a léčbu arteriální hypertenze ČSH 2017. Hypertenze a KV prevence 2018; 7(Suppl): 2-22.
    16. Vítovec J, ©pinar J, ©pinarová L. Léčba anémie a nedostatku ľeleza u chronického srdečního selhání. Kardiol Rev Int Med 2014; 16(5): 364-369.
    17. Damman K, Testani JM. The kidney in heart failure: an update. Eur Heart J 2015; 36(23): 1437-1444. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehv010>. Go to original source... Go to PubMed...
    18. Guder G, Brenner S, Stork S et al. Chronic obstructive pulmonary disease in heart failure: accurate diagnosis and treatment. Eur J Heart Fail 2014; 16(12): 1-10. Dostupné z DOI: <http://dx.doi.org/10.1002/ejhf.183>. Go to original source... Go to PubMed...
    19. Kenchaiah S, Evans JC, Levy D et al. Obesity and the risk of heart failure. N Engl J Med 2002; 347(5): 305-313. <http://dx.doi.org/10.1056/NEJMoa020245>. Go to original source... Go to PubMed...
    20. Ludka O, Kára T, Drozdová A et al. Spánková apnoe a kardiovaskulární onemocnění. Kardiol Rev Int Med 2013; 15(2): 87-93.
    21. Nakamura S, Asai K, Kubota Y et al. Impact of sleep-disordered breathing and efficacy of positive airway pressure on mortality in patients with chronic heart failure and sleep-disordered breathing: a meta-analysis. Clin Res Cardiol 2015; 104(3): 208-216. Dostupné z DOI: <http://dx.doi.org/10.1007/s00392-014-0774-3>. Go to original source... Go to PubMed...
    22. Linhartová K. Kočková R, Línková H. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Cor Vasa 2017; 59(5): e562-e591. Dostupné z DOI: <https://doi.org/10.1016/j.crvasa.2017.10.006>. Go to original source...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.